This article is more than 5 years old. Information may no longer be current.

Spark Therapeutics reports $28.7 million net loss for second quarter

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Spark Therapeutics reported a $28.7 million net loss applicable to common stockholders for the second quarter compared with a net loss applicable to common stockholders of $14.3 million in the second quarter of 2015, according to a press release.

Basic and diluted net loss per common share was $1.04 compared with basic and diluted net loss per common share of $0.60 a year ago.

Revenue totaled $1.3 million due to a collaboration with Pfizer, which was the same amount as the second quarter of 2015.

Research and development expenses increased to $19.6 million compared with $9.3 million in the second quarter of 2015. General and administrative expenses increased to $10.7 million compared with $6.3 million.